Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trojantec Ltd
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Developed Antennapedia-based cell penetrating peptide platform for intracellular delivery; licensed TR-1 (p53/p21 re-activator) to SELLAS for Phase 1 in 2015 (ovarian, breast, colon cancers); licensed infectious diseases rights to Trojan Technologies USA for preclinical development.
- Therapeutic areas
- OncologyHematology
- Modalities
- ProteinCell penetrating peptideFusion protein
- Industry
- Biotech
02
Partnerships
SELLAS Life Sciences Group (exclusive license for TR-1)Trojan Technologies USA (license for infectious diseases)Imperial College London (technology origin)Imperial Innovations (patent assignment)
Beyond the preview
Go deeper on Trojantec Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trojantec Ltd.